Rare diseases
Investigational molecules
Locations
Ul. Kornela Ujejskiego 75, 85-168 Bydgoszcz, Poland
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy in Bydgoszcz, Poland specialises in clinical trials of conditions such as Systemic lupus erythematosus, Sjogren's syndrome, Psoriatic arthropathy, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in gastroenterology, focusing on innovative treatments for Crohn's Disease and Ulcerative Colitis. The center's studies aim to improve patient outcomes through novel therapeutic approaches.
By exploring new drug combinations and treatment regimens, the center contributes significantly to the understanding and management of these chronic conditions.
Specializing in oncology, the center conducts extensive research on various types of lymphomas and multiple myeloma. The focus is on developing targeted therapies that offer improved efficacy and safety profiles.
Through cutting-edge clinical trials, the center is advancing the treatment landscape for these hematological malignancies.
The center is a leader in rheumatology research, with a strong emphasis on autoimmune diseases such as Rheumatoid Arthritis and Systemic Lupus Erythematosus. The research aims to enhance therapeutic strategies and improve patient quality of life.
By investigating novel biologics and small molecules, the center is paving the way for more effective treatments.
In the field of cardiology, the center is dedicated to improving outcomes for patients with acute coronary syndrome and heart failure. Research efforts focus on optimizing antithrombotic therapies and heart failure management.
The center's work is instrumental in developing safer and more effective cardiovascular treatments.
With a strong focus on hematology, the center explores innovative treatments for Chronic Lymphocytic Leukemia and Paroxysmal Nocturnal Hemoglobinuria. The research aims to enhance therapeutic efficacy and patient outcomes.
Through rigorous clinical trials, the center is advancing the understanding and treatment of these complex blood disorders.
The center is a pioneer in immunology, focusing on conditions such as Primary Immunodeficiency Diseases and Idiopathic Inflammatory Myopathies. Research efforts are directed towards developing novel immunomodulatory therapies.
By advancing the understanding of immune system disorders, the center is contributing to the development of more effective treatments.
Clinical trials currently enrolling participants at this site.
BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus
PolandA study of navenibart for long-term safety in patients with hereditary angioedema
PolandStudy on Mechanical Thrombectomy and Acetylsalicylic Acid for Patients with Acute Ischemic Stroke from Large Vessel Blockage
PolandStudy on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus
PolandStudy on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome
PolandPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
PolandRamantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant
PolandA double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis
PolandPhase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments
PolandNipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
PolandQTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia
PolandTulisokibart for Psoriatic Arthritis in Adults
PolandGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
